glp 1 agonist insurance coverage GLP-1 - Why Employers Should Cover GLP-1s Paving the way for expanded

Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry

Brain Health and Neurological Benefits Exciting research shows that GLP-1 medications may have impressive effects on brain health: They reduce the risk of Alzheimers disease and dementia They help protect against Parkinsons disease They lower the risk of seizures They may reduce stroke risk and improve recovery after stroke They show benefits for Huntingtons disease in early studies A January 2025 study from Washington University found that people taking GLP-1 medications had a decreased risk of neurocognitive disorders like Alzheimers

It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to help break down sugar and fat, according to Chatham

IH has received nonfinancial support from AstraZeneca/Bristol Myers Squibb, Dexcom, GlaxoSmithKline, Insulet Corp., Janssen, Lexicon Pharmaceuticals, Medtronic, Merck & Co., Novo Nordisk, the Population Health Research Institute and Sanofi

Medicare Part D can cover Ozempic or Mounjaro for Type 2 diabetes but cannot cover Wegovy or Zepbound for weight loss

Lach-Trifilieff, E